Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
Pneumococcal (Pneumovax) in 2026
8 adverse event reports (-97% vs 2025)
2026 Reporting Summary
In 2026, 8 adverse event reports were filed for Pneumococcal (Pneumovax) in VAERS. This represents 0.0% of all 71,157 reports for this vaccine.
Of these reports, 0 mentioned death, 0 involved hospitalization, 1 required ER visits, and 1 reported disability.
Compared to the average of 1,871 reports per year for this vaccine, 2026 was below average (-100%).
💡 What This Means
In 2026, reporting for Pneumococcal (Pneumovax) was within typical ranges. As always, VAERS data reflects reports filed, not confirmed adverse events. Trends should be interpreted alongside vaccination volume and population health data.
All Years for Pneumococcal (Pneumovax)
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2025 | 252 | 0 | 15 |
| 2024 | 708 | 1 | 23 |
| 2023 | 604 | 1 | 29 |
| 2022 | 1,080 | 4 | 52 |
| 2021 | 1,682 | 9 | 53 |
| 2020 | 3,012 | 4 | 111 |
| 2019 | 3,608 | 10 | 149 |
| 2018 | 4,589 | 11 | 204 |
| 2017 | 5,458 | 7 | 181 |
| 2016 | 6,014 | 10 | 173 |
| 2015 | 3,583 | 10 | 170 |
| 2014 | 3,877 | 21 | 234 |
| 2013 | 3,251 | 12 | 207 |
| 2012 | 3,062 | 6 | 211 |
| 2011 | 2,650 | 3 | 151 |
| 2010 | 3,010 | 11 | 210 |
| 2009 | 2,398 | 16 | 177 |
| 2008 | 2,303 | 11 | 176 |
| 2007 | 2,291 | 6 | 151 |
| 2006 | 1,990 | 8 | 139 |
| 2005 | 1,783 | 4 | 118 |
| 2004 | 1,137 | 5 | 106 |
| 2003 | 1,388 | 12 | 67 |
| 2002 | 1,107 | 7 | 78 |
| 2001 | 1,011 | 8 | 60 |
| 2000 | 917 | 7 | 64 |
| 1999 | 978 | 11 | 69 |
| 1998 | 836 | 6 | 59 |
| 1997 | 616 | 8 | 55 |
| 1996 | 477 | 4 | 41 |
| 1995 | 564 | 6 | 51 |
| 1994 | 345 | 5 | 44 |
| 1993 | 237 | 2 | 33 |
| 1992 | 222 | 5 | 30 |
| 1991 | 215 | 1 | 23 |
| 1990 | 97 | 0 | 8 |
Understanding Yearly Data
Quick Facts
Data Source
This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.